| Name | Title | Contact Details |
|---|
MedMen Enterprises is a leading cannabis company in the U.S. with assets and operations nationwide. MedMen owns and operates licensed cannabis facilities in cultivation, manufacturing and retail, and is the most recognized cannabis brand in the world today. MedMen brings class leading operational expertise and unprecedented investment to the fast changing and fast-growing cannabis industry as it moves from its gray market legacy to a fully regulated, legitimate and commercially viable market. Based in Los Angeles, MedMen employs over 1,100 team members across the U.S. It was founded in 2010 by Adam Bierman and Andrew Modlin, two visionary entrepreneurs who saw not just a tremendous business opportunity in the growing legalization of marijuana, but a chance to redefine our society`s relationship with cannabis. The federal prohibition has had a disastrous impact, overpopulating our prisons and enriching violent drug cartels while keeping a relatively benign substance with proven benefits out of the reach of law abiding citizens. MedMen supports sensible, clear and just drug laws that strengthen communities and create economic opportunities. The company is the single largest financial supporter of progressive marijuana laws at the local, state and federal levels, giving directly to pro-legalization groups, industry organizations and political candidates.
CCStpa is a Eagan, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
APS Healthcare, Inc. is a comprehensive managed behavioral healthcare company focusing on the management of mental health services and substance abuse treatment, often referred to together as behavioral healthcare.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.
SciMar is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.